CELL INTELLIGENCE · 肿瘤细胞治疗研究

胰腺肿瘤微环境中代谢-免疫交互的机制及临床意义

Mechanism and clinical relevance of metabolic-immune cross-talk in pancreatic tumor microenvironment.

碳水化合物抗原 19-9 聚糖是胰腺及其他实体瘤中 CAR-T 细胞治疗的可行靶点

The Carbohydrate Antigen 19-9 Glycan Is a Viable Target for Chimeric Antigen Receptor T-Cell Therapy in Pancreatic and Other Solid Tumors.

我们的研究结果表明，CA19-9 CAR-T 细胞在多种临床前肿瘤模型中针对胃肠道癌症具有有效性，为进一步临床开发提供了依据。

单日非激活 IL-18 武装 CAR-T 细胞建立持久的干样状态并增强持久性

Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence.

静息肿瘤细胞塑造胰腺癌免疫抑制微环境

Quiescent tumor cells shape the immunosuppressive microenvironment in pancreatic cancer.

工程化靶向近膜区的抗间皮素 CAR-T 细胞：一种可抵抗脱落抗原的新型结合分子以增强对卵巢癌和胰腺癌的疗效

Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian an

通过临床可行的联合方案优化胰腺癌 CAR-T 细胞治疗

Optimizing CAR T cell therapy in pancreatic cancer through clinically actionable combinations.

PSCA CAR Vδ1 T 细胞：胰腺癌更安全的现货型 CAR-T 疗法？

PSCA CAR Vδ1 T cells: a safer off-the-shelf CAR T therapy for pancreatic cancer?

构建功能优化的全人源 B7-H3 CAR-T 细胞以增强实体瘤治疗

Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy.

靶向脂质纳米颗粒递送 FAP-CAR mRNA 实现强效体内 T 细胞工程化以对抗胰腺肿瘤

Targeted Lipid Nanoparticle Delivery of FAP-CAR mRNA Enables Potent In Vivo T-cell Engineering against Pancreatic Tumors.

针对 Dickkopf-1-A2 复合物工程化的 T 细胞可用于治疗 HLA-A2(+) 实体瘤和血液系统肿瘤

T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2(+) solid and hematologic cancers.